Literature DB >> 10537312

Ataxia telangiectasia mutated deficiency affects astrocyte growth but not radiosensitivity.

E C Gosink1, M J Chong, P J McKinnon.   

Abstract

The cancer-prone neurodegenerative disorder, ataxia telangiectasia (A-T), results from mutations of ATM (ataxia telangiectasia mutated). Individuals with A-T are also hypersensitive to ionizing radiation (IR). Cultured cells from A-T individuals or Atm-/- mice have cell cycle and growth defects and are generally considered radiosensitive. However, it has been shown recently that cell populations in the Atm-/- central nervous system are radioresistant. To define specific IR sensitivities of neural populations, we analyzed Atm-/- astrocytes. Here we show that Atm-/- astrocytes exhibit premature senescence, express constitutively high levels of p21, and have impaired p53 stabilization. However, in contrast to radiosensitive Atm-/- fibroblasts and radioresistant Atm-/- neurons, survival of Atm-/- astrocytes after IR was similar to wild-type astrocytes. Additionally, p53-null astrocytes, but not fibroblasts, were moderately more radioresistant than their wild-type counterparts, suggesting that the deficit in p53 stabilization observed in Atm-null cells is not a measure of radiation susceptibility. Thus, in astrocytes, the function of Atm in cellular growth and radiosensitivity is distinct. These data may have implications for ATM disruption strategies as a radiosensitizing treatment for brain tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537312

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.

Authors:  Sarah E Golding; Elizabeth Rosenberg; Bret R Adams; Shayalini Wignarajah; Jason M Beckta; Mark J O'Connor; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-03-15       Impact factor: 4.534

2.  Mutation of ataxia-telangiectasia mutated is associated with dysfunctional glutathione homeostasis in cerebellar astroglia.

Authors:  Andrew Campbell; Jared Bushman; Joshua Munger; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Glia       Date:  2015-10-15       Impact factor: 7.452

Review 3.  Ataxia-telangiectasia and related diseases.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

4.  A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia.

Authors:  Dorit Raz-Prag; Ronit Galron; Niva Segev-Amzaleg; Arieh S Solomon; Yosef Shiloh; Ari Barzilai; Dan Frenkel
Journal:  Am J Pathol       Date:  2011-07-19       Impact factor: 4.307

5.  Elevated Cu/Zn-SOD exacerbates radiation sensitivity and hematopoietic abnormalities of Atm-deficient mice.

Authors:  Y Peter; G Rotman; J Lotem; A Elson; Y Shiloh; Y Groner
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

Review 6.  The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.682

7.  Cytoplasmic ATM in neurons modulates synaptic function.

Authors:  Jiali Li; Yu R Han; Mark R Plummer; Karl Herrup
Journal:  Curr Biol       Date:  2009-12-03       Impact factor: 10.834

8.  Oxidative stress is linked to ERK1/2-p16 signaling-mediated growth defect in ATM-deficient astrocytes.

Authors:  Jeesun Kim; Paul K Y Wong
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

9.  A Model for p38MAPK-Induced Astrocyte Senescence.

Authors:  José C M Mombach; Bruno Vendrusculo; Cristhian A Bugs
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

10.  Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.

Authors:  Ross Carruthers; Shafiq U Ahmed; Karen Strathdee; Natividad Gomez-Roman; Evelyn Amoah-Buahin; Colin Watts; Anthony J Chalmers
Journal:  Mol Oncol       Date:  2014-08-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.